» Articles » PMID: 28232146

Effects of Klotho Deletion from Bone During Chronic Kidney Disease

Overview
Journal Bone
Date 2017 Feb 25
PMID 28232146
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Klotho is a type I transmembrane protein that acts as a permissive co-receptor for FGF23 and helps to maintain proper mineral metabolism. Mice carrying a loss-of-function mutation in either the Klotho or Fgf23 gene develop many similar phenotypes including osteoporosis. Based on these observations it was hypothesized that the bone phenotypes in Klotho- and Fgf23-null mice may be mediated through a common signaling pathway. Recent improvements in antibody specificity have shown that osteoblasts and osteocytes, which produce FGF23, also express low amount of membrane Klotho. But, the role of Klotho in bone is still largely unclear. In this review we summarize the literature and show that Klotho has an FGF23 dependent and independent effect in bone.

Citing Articles

Association of serum Klotho with the severity and mortality among adults with cardiovascular-kidney-metabolic syndrome.

Tang J, Xu Z, Ren L, Xu J, Chen X, Jin Y Lipids Health Dis. 2024; 23(1):408.

PMID: 39695774 PMC: 11654297. DOI: 10.1186/s12944-024-02400-w.


Relationship of the bone phenotype of the Klotho mutant mouse model of accelerated aging to changes in skeletal architecture that occur with chronological aging.

Verlinden L, Li S, Veldurthy V, Carmeliet G, Christakos S Front Endocrinol (Lausanne). 2024; 15:1310466.

PMID: 38352710 PMC: 10861770. DOI: 10.3389/fendo.2024.1310466.


Klotho in Osx-mesenchymal progenitors exerts pro-osteogenic and anti-inflammatory effects during mandibular alveolar bone formation and repair.

Fan Y, Cui C, Rosen C, Sato T, Xu R, Li P Signal Transduct Target Ther. 2022; 7(1):155.

PMID: 35538062 PMC: 9090922. DOI: 10.1038/s41392-022-00957-5.


Protective Effects of Moderate Ca Supplementation against Cd-Induced Bone Damage under Different Population-Relevant Doses in Young Female Rats.

Huang X, Liu T, Zhao M, Fu H, Wang J, Xu Q Nutrients. 2019; 11(4).

PMID: 30991710 PMC: 6521033. DOI: 10.3390/nu11040849.


Updates in CKD-Associated Osteoporosis.

Khairallah P, Nickolas T Curr Osteoporos Rep. 2018; 16(6):712-723.

PMID: 30353319 PMC: 6264896. DOI: 10.1007/s11914-018-0491-3.


References
1.
Coresh J, Selvin E, Stevens L, Manzi J, Kusek J, Eggers P . Prevalence of chronic kidney disease in the United States. JAMA. 2007; 298(17):2038-47. DOI: 10.1001/jama.298.17.2038. View

2.
Olauson H, Lindberg K, Amin R, Jia T, Wernerson A, Andersson G . Targeted deletion of Klotho in kidney distal tubule disrupts mineral metabolism. J Am Soc Nephrol. 2012; 23(10):1641-51. PMC: 3458458. DOI: 10.1681/ASN.2012010048. View

3.
de Jager D, Grootendorst D, Jager K, van Dijk P, Tomas L, Ansell D . Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA. 2009; 302(16):1782-9. DOI: 10.1001/jama.2009.1488. View

4.
Yuan Q, Sato T, Densmore M, Saito H, Schuler C, Erben R . FGF-23/Klotho signaling is not essential for the phosphaturic and anabolic functions of PTH. J Bone Miner Res. 2011; 26(9):2026-35. PMC: 4343543. DOI: 10.1002/jbmr.433. View

5.
Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G . Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol. 2005; 16(7):2205-15. DOI: 10.1681/ASN.2005010052. View